CD47 and neoplasm: As anticipated, mechanistic insights from many of these studies have shown that the enhanced phagocytosis and immune sensing of tumor cells exhibited by DC following CD47 blockade promotes tumor Ag cross‐presentation and the activation of antitumor T cells whose effector functions are then bolstered by interference with the CTLA‐4 and PD‐1 pathways.